← All trials
NCT05949801
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 13, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Sep 30, 2024
- First posted
- Jul 18, 2023
- Last posted
- Jul 18, 2023
- Enrollment
- 198
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ZensunLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.